What are your top takeaways in Hematologic Malignancies from ASH 2024?

Years ago, I was consulting with a patient who had moved to the Pacific Northwest after being diagnosed elsewhere with multiple myeloma. After engaging in initial pleasantries and just before I was about to peel away the specifics of her medical history, she stopped me in my tracks. “Did you go to A...

1. Abstract 1009 - Multiple important studies were presented at the recently concluded ASH meeting. From the CLL perspective, one of the most impactful studies was the AMPLIFY clinical trial that compared acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-li...

From myeloma data, I think the following were notable:

1. CEPHEUS trial once again confirmed the benefit of the CD38 monoclonal antibody-based quadruplet therapy among patients with newly diagnosed transplant-ineligible patients.
2. The report from phase I/II trial of cevostamab was impressive in late re...

1. Abstract #773 Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study
This will revolutionize the way we practice, both in our myeloma clinics and in primary care physician clinics.
Dara...

1. Abstract 240 and LBA-6 for mantle cell lymphoma have finally answered the question about the benefit of autologous stem cell transplant for MCL. In short, the value for high dose chemo has been reduced in the era of small molecule therapy and cellular immunotherapy. While some subset of patients ma...

1. There was very little in the AML world, only the Ziftomenib with 7&3 that had a 100% response rate (Zeiden et al.).
2. In ALL, the Pediatric study confirming ECOG1910 presented in the plenary was meaningful.
3. Another meaningful abstract came from Dr. Mascarenhas during the MPN session of the phase 3 Ka...

1. EA4151 – The study evaluated the benefit of ASCT vs. maintenance rituximab in patients with MRD undetectable MCL. The study indicated a lack of benefit of ASCT in MRD undetectable patients albeit with an overall short follow-up. Major questions remain about
1. Is this needed based on updated data fro...

There were so many excellent abstracts/presentations from which to choose, but here are three that I found particularly interesting.

1. Abstract 362, the CEPHEUS trial. This trial has helped establish DaraRVd à DaraRd as a standard of care for newly diagnosed transplant ineligible patients. There are s...

1. Data from Arcillex CAR-T
2. Daratumumab smoldering myeloma phase 3 study
3. Early phase bispecific combination data

1. ECOG-ACRIN EA4151 (Fenske). An important study in Mantle Cell lymphoma. Patients in CR1 who achieved uMRD at 10^-6 did not benefit from auto-HCT + rituximab maintenance compared to no transplant. Important and practice changing regarding the role of auto-HCT in MCL.
   
   
2. TRIANGLE trial - European MCL ne...

1. The menin inhibitors have potential in AML with NPM1 and KMT2a aberrations, and optimal use and comparisons of the several inhibitors under development will need to be pursued in the near future.
2. While triplet therapy in AML has potential (venetoclax + HMA + targeted agent of interest) and has prom...